COLORADO SPRINGS, Colo.,
July 29, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, applauds the Editorial Board of the
New York Times for taking a strong
position in opposition to current federal law on cannabis in its
Sunday, July 27, 2014
publication. The New York Times
also announces a series of upcoming editorials and articles this
week exploring the issue called "High Time: An Editorial
Series on Marijuana Legalization".
"The federal government should repeal the ban on marijuana....
We reached that conclusion after a great deal of discussion among
the members of The Times's Editorial Board, inspired by a rapidly
growing movement among the states to reform marijuana laws," stated
the New York Times Editorial Board's sweeping statement.
"As perhaps the most respected newspaper in the United States, it is more than noteworthy
that the editorial board of the New York
Times has taken such a strong stance on cannabis
legalization, relying in part on the evidence of the success of
medical benefits," said Chad S.
Johnson, Director, COO and General Counsel, Cannabis
Science, Inc. "As a bell weather of the view of American
citizens, the New York Times' action is
yet another example of prestigious, mainstream journalistic
institution like CNN and Dr. Sanjay
Gupta in openly challenging the irrational federal
classification of cannabis."
Also this weekend, the New York
Times ran the first editorial and article in its "High Time"
series: "Let States Decide on Marijuana" by David Firestone and "The Public Lightens Up
About Weed" by Juliet Lapidos.
At High Time: Repeal Prohibition, Again, you may view the
full editorial board's statement and the additional editorial and
article may be viewed through the following links: Let States
Decide on Marijuana and The Public Lightens Up About Weed,
respectively.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.